+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

HIV Drugs: Global Strategic Business Report

  • PDF Icon

    Report

  • 164 Pages
  • December 2023
  • Region: Global
  • Global Industry Analysts, Inc
  • ID: 1227763

Quick Summary:

In an increasingly competitive global market, maneuvering the intricacies of the HIV Drugs sector can represent a significant undertaking. Our latest comprehensive market research report is designed to equip business executives like you with the vital information you need to ensure a competitive edge.

The HIV Drugs market, estimated to swell to US$44.5 Billion by 2030, offers immense opportunities for strategic positioning and growth across various segments, including Combination HIV Medicines and Integrase Inhibitors (INIs). Prospects for market penetration encompass a global landscape, with noteworthy potential in markets such as the U.S., China, Japan, Canada, Germany, and the rising Asia-Pacific region.

Our estimates come enriched with exclusive insights into 52 key competitors. This report also provides invaluable quantitative data on market presence across different regions and global competitiveness. Additionally, gain unlimited access to our digital archives, research platform, and complimentary updates for a year. Secure your strategic advantage - invest in our refined market intelligence today.

Global HIV Drugs Market to Reach $44.5 Billion by 2030

The global market for HIV Drugs estimated at US$29.6 Billion in the year 2022, is projected to reach a revised size of US$44.5 Billion by 2030, growing at a CAGR of 5.3% over the analysis period 2022-2030. Combination HIV Medicines, one of the segments analyzed in the report, is projected to record a 5.2% CAGR and reach US$29 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Integrase Inhibitors (INIs) segment is readjusted to a revised 5.7% CAGR for the next 8-year period.

The U.S. Market is Estimated at $8.1 Billion, While China is Forecast to Grow at 8.8% CAGR

The HIV Drugs market in the U.S. is estimated at US$8.1 Billion in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$9.7 Billion by the year 2030 trailing a CAGR of 8.8% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 2.7% and 4.3% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 3.5% CAGR. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$6.1 Billion by the year 2030.

Select Competitors (Total 52 Featured) -

  • AbbVie, Inc.
  • AstraZeneca PLC
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Company
  • Cipla Ltd.
  • Daiichi Sankyo Co., Ltd.
  • Emcure Pharmaceuticals Pvt., Ltd.
  • F. Hoffmann-La Roche AG
  • Gilead Sciences, Inc.
  • Hetero Drugs Ltd.
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Teva Pharmaceutical Industries Ltd.
  • ViiV Healthcare

What's New?

  • Special coverage on Russia-Ukraine war; global inflation; easing of zero-Covid policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.
  • Global competitiveness and key competitor percentage market shares
  • Market presence across multiple geographies - Strong/Active/Niche/Trivial
  • Online interactive peer-to-peer collaborative bespoke updates
  • Access to digital archives and Research Platform
  • Complimentary updates for one year

Frequently Asked Questions about the Global Market for HIV Drugs

What is the estimated value of the Global Market for HIV Drugs?

The Global Market for HIV Drugs was estimated to be valued at $29.6 Billion in 2022.

What is the growth rate of the Global Market for HIV Drugs?

The growth rate of the Global Market for HIV Drugs is 5.2%, with an estimated value of $44.5 Billion by 2030.

What is the forecasted size of the Global Market for HIV Drugs?

The Global Market for HIV Drugs is estimated to be worth $44.5 Billion by 2030.

Who are the key companies in the Global Market for HIV Drugs?

Key companies in the Global Market for HIV Drugs include AbbVie, Inc., AstraZeneca PLC, Boehringer Ingelheim GmbH, Bristol, Myers Squibb Company, Cipla Ltd., Daiichi Sankyo Co., Ltd., Emcure Pharmaceuticals Pvt., Ltd., F. Hoffmann and La Roche AG.

Table of Contents

I. METHODOLOGYII. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • HIV Drugs - Global Key Competitors Percentage Market Share in 2022 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
  • Impact of Covid-19 and a Looming Global Recession
2. FOCUS ON SELECT PLAYERS3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
  • Table 1: World Recent Past, Current & Future Analysis for HIV Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 2: World Historic Review for HIV Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
  • Table 3: World 18-Year Perspective for HIV Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2012, 2023 & 2030
  • Table 4: World Recent Past, Current & Future Analysis for Combination HIV Medicines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 5: World Historic Review for Combination HIV Medicines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
  • Table 6: World 18-Year Perspective for Combination HIV Medicines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2023 & 2030
  • Table 7: World Recent Past, Current & Future Analysis for Integrase Inhibitors (INIs) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 8: World Historic Review for Integrase Inhibitors (INIs) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
  • Table 9: World 18-Year Perspective for Integrase Inhibitors (INIs) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2023 & 2030
  • Table 10: World Recent Past, Current & Future Analysis for Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 11: World Historic Review for Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
  • Table 12: World 18-Year Perspective for Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2023 & 2030
  • Table 13: World Recent Past, Current & Future Analysis for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 14: World Historic Review for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
  • Table 15: World 18-Year Perspective for Other Drug Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2023 & 2030
  • Table 16: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 17: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
  • Table 18: World 18-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2023 & 2030
  • Table 19: World Recent Past, Current & Future Analysis for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 20: World Historic Review for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
  • Table 21: World 18-Year Perspective for Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2023 & 2030
  • Table 22: World Recent Past, Current & Future Analysis for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 23: World Historic Review for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
  • Table 24: World 18-Year Perspective for Online Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2023 & 2030
  • Table 25: World Recent Past, Current & Future Analysis for Other Distribution Channels by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 26: World Historic Review for Other Distribution Channels by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
  • Table 27: World 18-Year Perspective for Other Distribution Channels by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2023 & 2030
  • Table 28: World HIV Drugs Market Analysis of Annual Sales in US$ Million for Years 2012 through 2030
III. MARKET ANALYSIS
UNITED STATES
  • HIV Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2023 (E)
CANADA
JAPAN
  • HIV Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2023 (E)
CHINA
  • HIV Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2023 (E)
EUROPE
  • HIV Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2023 (E)
FRANCE
  • HIV Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2023 (E)
GERMANY
  • HIV Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2023 (E)
ITALY
UNITED KINGDOM
  • HIV Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2023 (E)
SPAINRUSSIAREST OF EUROPE
ASIA-PACIFIC
  • HIV Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2023 (E)
AUSTRALIA
  • HIV Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2023 (E)
INDIA
  • HIV Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2023 (E)
SOUTH KOREAREST OF ASIA-PACIFIC
LATIN AMERICA
  • HIV Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2023 (E)
ARGENTINABRAZILMEXICOREST OF LATIN AMERICA
MIDDLE EAST
  • HIV Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2023 (E)
IRANISRAELSAUDI ARABIAUNITED ARAB EMIRATESREST OF MIDDLE EAST
AFRICA
  • HIV Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2023 (E)
IV. COMPETITION

Companies Mentioned

A selection of companies mentioned in this report includes:

  • AbbVie, Inc.
  • AstraZeneca PLC
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Company
  • Cipla Ltd.
  • Daiichi Sankyo Co., Ltd.
  • Emcure Pharmaceuticals Pvt., Ltd.
  • F. Hoffmann-La Roche AG
  • Gilead Sciences, Inc.
  • Hetero Drugs Ltd.
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Teva Pharmaceutical Industries Ltd.
  • ViiV Healthcare